Funding to support research where quantitative and analytical approaches, processes, and/or systems are developed and/or used to obtain knowledge and insights from large and/or complex sets of prostate cancer data.
The US Department of Defense (DoD) Congressionally Directed Medical Research Program (CDMRP) was established in 1992 and is one of the largest funders of clinical research in the United States. CDMRP aims to foster novel approaches to biomedical research in response to the expressed needs of its stakeholders (the American public, the U.S military, and Congress). CDMRP fulfils this mission by funding high impact, high risk and high gain projects that other agencies may not venture to fund. This is why all of the programmes managed by CDMRP share the common goal of advancing paradigm shifting research, solutions that will lead to cures or improvements in patient care, or breakthrough technologies and resources for clinical benefit.
The aim of the Prostate Cancer Research Program (PCRP) is to support research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all men experiencing the impact of the disease.
All applications for PCRP funding are required to address one or more of the PCRP Overarching Challenges.
The CDMRP PCRP Data Science Award supports research where quantitative and analytical approaches, processes, and/or systems are developed and/or used to obtain knowledge and insights from large and/or complex sets of prostate cancer data.
Applications may propose development of a new data-science driven tool or apply an existing tool or method to gather and analyse information from large data sets with the intent of advancing prostate cancer research and patient care relative to the PCRP Overarching Challenges.
Research efforts must be built upon the logic, concepts, and methods of one or more of the following research areas as they pertain to prostate cancer:
Artificial Intelligence and machine learning.
Analysis of -omics data.
Analysis of clinically annotated datasets.
Clinical research is allowed, but must be retrospective. Prospective recruitment of human subjects and/or clinical trials are not allowed.
The award mechanism includes a Partnering Principal Investigator (PI) Option, which allows two PIs (Initiating and Partnering PIs) to collaborate on a single application. Collaborations between data scientists and clinicians are highly encouraged. At least one of the submitting or partnering PIs must have expertise in prostate cancer basic and/or clinical research.